Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Mesothelioma × Ramucirumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Stomach Neoplasms 14 Carcinoma, Non-Small-Cell Lung 11 Neoplasms 8 Carcinoma, Hepatocellular 7 Colorectal Neoplasms 6 Colonic Neoplasms 5 Breast Neoplasms 5 Adenocarcinoma 5 Carcinoma, Renal Cell 4 Urethral Neoplasms 3 Rectal Neoplasms 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Liver Neoplasms 3 Esophageal Neoplasms 3 Urinary Bladder Neoplasms 2 Ureteral Neoplasms 2 Pancreatic Neoplasms 2 Melanoma 2 Malignant Solid Tumor 2 Carcinoma, Transitional Cell 2 Thymoma 1 Solid Tumors 1 Recurrence 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Metastatic Gastric Adenocarcinoma 1 Mesothelioma 1 Lymphoma, Mantle-Cell 1 Liver Diseases 1

Interventions

Pemetrexed 20 Cisplatin 16 Nivolumab 8 Gemcitabine 7 Ipilimumab 6 Carboplatin 6 tazemetostat 3 pembrolizumab 3 durvalumab 3 Fluorouracil 3 Bevacizumab 3 niraparib 2 budigalimab 2 belinostat 2 anetumab ravtansine 2 Vinorelbine 2 Radiotherapy, Intensity-Modulated 2 Paclitaxel 2 PM 01183 2 Oxaliplatin 2 Imatinib Mesylate 2 Everolimus 2 Erlotinib Hydrochloride 2 Doxorubicin 2 venetoclax 1 tremelimumab 1 trametinib 1 spartalizumab 1 sodium thiosulfate 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03560973 2025-03-13

RAMES

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡